TRACY LEA KLAYTON M.D.
Prescription History 1497948947
Radiology - Radiation Oncology in Kittanning, PA


Quality Rating: 93.78 out of 100 score

NPI Status: Active since August 18, 2007

Contact Information

1 NOLTE DR
KITTANNING, PA
ZIP 16201
Phone: (724) 543-8690
Fax: (724) 543-8503

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for TRACY LEA KLAYTON M.D., an active Radiation Oncology specialist practicing in Kittanning, PA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 79 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 37 claims alone.

Medication Index

No matching medications currently found on file.

Bicalutamide

Generic Formulation: BicalutamideSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
PA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills37.5
Peer Average Days Supply1,090
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $261.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.08

State Avg Cost Per Claim

$35.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bicalutamide is used to treat prostate cancer. This medication works by blocking the action of male hormones in the prostate, slowing the growth of cancer cells. This medication should not be used in women and children.

Lidocaine Hcl Viscous

Generic Formulation: Lidocaine HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 102
PA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply171
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $320.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.71

State Avg Cost Per Claim

$17.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used on the skin to stop itching and pain from certain skin conditions (such as scrapes, minor burns, eczema, insect bites) and to treat minor discomfort and itching caused by hemorrhoids and certain other problems of the genital/anal area (such as anal fissures, itching around the vagina/rectum). Some forms of this medication are also used to decrease discomfort or pain during certain medical procedures/exams (such as sigmoidoscopy, cystoscopy). Lidocaine is a local anesthetic that works by causing temporary numbness/loss of feeling in the skin and mucous membranes.

Pentoxifylline

Generic Formulation: PentoxifyllineSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.1
Days Supply 513
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply820
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $655.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.56

State Avg Cost Per Claim

$31.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production.

Therapeutic Applications

This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease). Pentoxifylline can decrease the muscle aching/pain/cramps during exercise, including walking, that occur with intermittent claudication. Pentoxifylline belongs to a class of drugs known as hemorrheologic agents. It works by helping blood flow more easily through narrowed arteries. This increases the amount of oxygen that can be delivered by the blood when the muscles need more (such as during exercise) thereby increasing walking distance and duration.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 37
30-Day Fills 54.3
Days Supply 1,630
PA State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills185.5
Peer Average Days Supply5,393
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.8% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $633.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.11

State Avg Cost Per Claim

$19.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like TRACY LEA KLAYTON M.D. provides transparency into local medical care patterns within Kittanning, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.